Figure 1 | Scientific Reports

Figure 1

From: Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH

Figure 1

CANA attenuates hepatic steatosis in WD-fed MC4R-KO mice. The changes in (a) blood glucose level, (b) food intake, and (c) body weight during CANA treatment for 20 weeks. Weights of the (d) liver and (e) epididymal fat after 8 and 20 weeks of CANA treatment. (f) Hematoxylin and eosin (HE) staining and (g) triglyceride (TG) content of the liver. (h) Expression levels of lipogenesis-related genes in the liver. (i) Serum ALT levels. WT, wild type; SD, standard diet; WD, Western diet; CANA, canagliflozin. Original magnification, x200. Scale bars, 100 μm. *p < 0.05, **p < 0.01 vs MC4R-KO/WD. Statistical analyses were performed using two-way (a,b and c) or one-way ANOVA (d,e,g,h and i) followed by Bonferroni post hoc test; MC4R-KO/WD and MC4R-KO/WD/CANA was pre-selected as a subset of means to compare. n = 15.

Back to article page